Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Bayer

Status: Completed

Conditions: Liver Neoplasms

Treatments: Drug: Regorafenib (Stivarga, BAY73-4506)

Study type: Observational

Funder types: Industry

Identifiers

NCT03289273

19244

EUPAS20981 (Registry Identifier)

Details and patient eligibility

About

Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)

Enrollment: 1,010 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with confirmed diagnosis of unresectable HCC
• Physician-initiated decision to treat with regorafenib (prior to study enrollment)

Exclusion criteria

• Participation in an investigational program with interventions outside of routine clinical practice
• Past treatment with regorafenib

Trial design

1,010 participants in 1 patient group

uHCC patients treated with regorafenib

Description:

Patients with a confirmed diagnosis of uHCC and for whom a decision to treat with regorafenib has been made (by the treating physician)

Treatment:

Drug: Regorafenib (Stivarga, BAY73-4506)